Recombinant CD3 (Teplizumab Biosimilar) antibody

Catalog No. ABIN7795117

The Humanized Monoclonal anti-CD3 (Teplizumab Biosimilar) antibody (ABIN7795117) specifically detects CD3 (Teplizumab Biosimilar) in FACS and in vivo. The antibody is reactive with Human samples.

Quick Overview for Recombinant CD3 (Teplizumab Biosimilar) antibody (ABIN7795117)

Target: CD3 (Teplizumab Biosimilar)

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Humanized

Clonality: Monoclonal

Conjugate: This CD3 (Teplizumab Biosimilar) antibody is un-conjugated

Application: Flow Cytometry (FACS), In vivo Studies (in vivo)

Grade: Research Grade

Product Details anti-CD3 (Teplizumab Biosimilar) Antibody

Expression System: Mammalian cells

Purpose: Teplizumab Biosimilar, Human CD3e Monoclonal Antibody

Characteristics: Teplizumab biosimilar uses the same protein sequences as the therapeutic antibody teplizumab (humanized OKT3). A fully human monoclonal antibody that binds to CD3 epsilon of the T cell receptor-CD3 complex, teplizumab (humanized OKT-3) is used to delay the onset of stage 3 type 1 diabetes (T1D) in people with stage 2 T1D.

Purification: Protein A or G affinity column

Purity: >95 % by reducing SDS-PAGE

Endotoxin Level: < 1 EU per 1 mg of the protein by the LAL method

Immunogen: Human CD3e

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: > 3 mg/mL

Storage: 4 °C,-20 °C

Storage Comment: Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.

Target Details for CD3 (Teplizumab Biosimilar)

Target: CD3 (Teplizumab Biosimilar)

Alternative Name: Teplizumab Biosimilar

Target Type: Biosimilar